Decentralized clinical trials were on the rise for years before COVID-19, but it was their success in keeping drug development programs on course during the pandemic that won these studies a new leading role in mainstream clinical research.

Nearly three out of four biopharmaceutical firms modified traditional protocols to adopt a form of decentralized studies also known as virtual or site-less trials in an effort to keep drug development programs on course during COVID-19. The strategy proved successful. Now, having gained a foothold in the biopharma industry, decentralized trials are poised to play a major role in drug development post-pandemic.

Download this eBook to learn about the integral role Direct-to-Patient Services play in the execution of decentralized trials and how sponsors can maximize these benefits to improve drug development.